Abstract
The purpose of the study was to calculate the seroprevalence of immunity to the varicella-zoster virus (VZV) infection and to evaluate the positive predictive value (PPV) and the negative predictive value (NPV) of the self-reported history of VZV infection in pregnant women. A cross sectional study was conducted in 18 private medical analysis laboratories. Information on socio-demographic characteristics and past history of varicella or zoster were collected using a questionnaire. Blood samples were obtained to determine the serological levels of past exposure to VZV. Overall, 486 pregnant women were recruited. The seroprevalence of VZV antibodies was 98.8%. Six women were seronegative, of whom four were primiparous. The PPV was high (99.5%) while the NPV was only 10.3%. The PPV is a reliable marker of prior VZV infection. In contrast, a negative history does not predict lack of immunity and should be completed by serological analysis which might be introduced to routine antenatal blood tests.
Similar content being viewed by others
Abbreviations
- NPV:
-
Negative predictive value
- PPV:
-
Positive predictive value
- VZV:
-
Varicella-zoster virus
References
Khoshnood B, Debruyne M, Lancon F, et al. Seroprevalence of varicella in the French population. Pediatr Infect Dis J 2006;25:41–4.
Sauerbrei A. Varicella-zoster virus infections in pregnancy. Intervirology 1998;41:191–6.
Mirlesse V. Varicelle pergravidique : place de l’imagerie dans le dépistage de l’atteinte fœtale. Revue du praticien Gynécologie et obstétrique 2004; 83:44–5.
Bonmarin I, Ndiaye B, Seringe E, Levy-Bruh D. Epidémiologie de la varicelle en France. Bull Epid Hebd 2005;8:29–32.
Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 1986;314:1542–6.
Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994;330:901–5.
Sauerbrei A, Wutzler P. Neonatal varicella. J Perinatol 2001;21:545–9.
Haddad J, Gut JP, Lokiec F. Prevention of foetal and neonatal transmission of the varicella-zoster virus. Pathol Biol (Paris) 1992;40:724–8.
Berrebi A, Assouline C, Ayoubi JM, et al. Varicelle et grossesse. Arch pediatr 1998;5:79–83.
Prober CG, Gershon AA, Grose C, et al. Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J 1990;9:865–9.
Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 1989;2:371–3.
Gatchalian S, Tabora C, Bermal N, et al. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12–24 months old. Am J Trop Med Hyg 2004;70:273–7.
Alanen A, Kahala K, Vahlberg T, et al. Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. BJOG 2005;112:50–6.
Linder N, Ferber A, Kopilov U, et al. Reported exposure to chickenpox: a predictor of positive anti-varicella-zoster antibodies in parturient women. Fetal Diagn Ther 2001;16:423–6.
Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994;343(8912):1548–51.
Salleras L, Dominguez A, Vidal J, et al. Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 2000;19:183–8.
Wutzler P, Farber I, Wagenpfeil S, et al. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2001;20:121–4.
Dayan GH, Panero MS, Debbag R, et al. Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002. J Clin Microbiol 2004;42:5698–5704.
Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998;3:886–890.
Goldberg JM, Ziel HK, Burchette R. Evaluation of varicella immune status in an obstetric population in relation to place of birth. Am J Perinatol 2002;19:387–394.
Plourd DM, Austin K. Correlation of a reported history of chickenpox with seropositive immunity in pregnant women. J Reprod Med 2005;50:779–783.
Knowles SJ, Grundy K, Cahill I, Cafferkey MT. Susceptibility to infectious rash illness in pregnant women from diverse geographical regions. Commun Dis Public Health 2004;7:344–8.
Saadatian-Elahi M, Mekki Y, Del Signore C, Lina B, Derrough T, Caulin E, Vanhems P. Séroprévalence de la varicelle chez les femmes enceintes dans le Rhône. BEH 2006;39:294–6.
Suarez Gonzalez A, Otero Guerra L, De La Guerra GV, et al. Varicella and parvovirus B19 immunity among pregnant women in Gijon, Spain. Med Clin (Barc) 2002;119:171–3.
Acknowledgments
The authors would like to thank all members of laboratories who assisted in the collection of the data. In particular, we acknowledge the efforts of Drs. Thierry, Julien, Accominotti, Paret, Soucheleau, Sellem, Trepo, Mazuyer, Hue, Gazzano, Gleize, Accominotti, Martinet, Richard, Chabaud-Sassoulas, Thomé, Zaoui, Marin-laflèche, Orfeuvre, Guiraud, Benzoni, Barrier, and Guillet.
This work was supported by Sanofi Pasteur MSD.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saadatian-Elahi, M., Mekki, Y., Del Signore, C. et al. Seroprevalence of varicella antibodies among pregnant women in Lyon-France. Eur J Epidemiol 22, 405–409 (2007). https://doi.org/10.1007/s10654-007-9136-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-007-9136-z